Nicole DeFeudis is an Editor at Endpoints News. She specializes in biopharma reporting, focusing on themes such as pharmaceuticals, healthcare administration, and public health. Nicole's work has been featured in New England Public Media, World Wealth Journal, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nicole's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly around regulatory approvals, legal policy regulation, and government announcements. She appears to be interested in stories related to FDA approvals, drug pricing, mergers and acquisitions within the pharmaceutical space.
To effectively reach out to Nicole with a pitch or as a source for her articles, it would be beneficial to provide insights or expertise related to recent developments in FDA regulations and approvals, legal challenges faced by pharmaceutical companies such as patent disputes or antitrust issues. Additionally, commentary on the implications of regulatory changes on drug pricing could also resonate well with her coverage focus.
It is important to note that Nicole tends to cover topics without geographic constraints explicitly mentioned. Therefore, pitches should focus on providing broader industry-specific insights rather than region-specific news unless otherwise indicated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Nicole Defeudis
AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B-cell lymphoma.
By: Nicole Defeudis
Sandoz unveiled a direct-to-consumer platform, starting off with a single medication for now as the generic drugmaker adopts a system that several brand-name manufacturers are using to cut out-of-pocket costs for some patients.
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Nicole Defeudis
Tampa General Hospital sued Eli Lilly over revoked 340B discounts, citing Florida unfair trade practices law. The hospital faces 25-50% higher drug costs, including 35.9% more for Mounjaro.
By: Nicole DeFeudis
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Nicole DeFeudis
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Gelman, Nicole DeFeudis
Welcome back to Endpoints Weekly! Don't miss Ryan Cross' deep dive into the paranoia caused by competition with China. Ryan writes that …
By: Nicole Defeudis
The embattled venture firm Apple Tree Partners has suffered a loss in a Cayman Island court case against its main limited partner.
